- Home
- CMMB vs SEGG Comparison
CMMB vs SEGG Comparison
Compare CMMB & SEGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- SEGG
- Stock Information
- Founded
- CMMB 2004
- SEGG N/A
- Country
- CMMB Israel
- SEGG United States
- Employees
- CMMB N/A
- SEGG 12
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- SEGG Computer Software: Prepackaged Software
- Sector
- CMMB Health Care
- SEGG Technology
- Exchange
- CMMB Nasdaq
- SEGG Nasdaq
- Market Cap
- CMMB 22.0M
- SEGG 19.7M
- IPO Year
- CMMB N/A
- SEGG 2023
- Fundamental
- Price
- CMMB $3.02
- SEGG $6.31
- Analyst Decision
- CMMB Strong Buy
- SEGG
- Analyst Count
- CMMB 2
- SEGG 0
- Target Price
- CMMB $26.50
- SEGG N/A
- AVG Volume (30 Days)
- CMMB 108.4K
- SEGG N/A
- Earning Date
- CMMB 08-14-2025
- SEGG N/A
- Dividend Yield
- CMMB N/A
- SEGG N/A
- EPS Growth
- CMMB N/A
- SEGG N/A
- EPS
- CMMB N/A
- SEGG N/A
- Revenue
- CMMB N/A
- SEGG N/A
- Revenue This Year
- CMMB N/A
- SEGG N/A
- Revenue Next Year
- CMMB N/A
- SEGG N/A
- P/E Ratio
- CMMB N/A
- SEGG N/A
- Revenue Growth
- CMMB N/A
- SEGG N/A
- 52 Week Low
- CMMB $3.02
- SEGG N/A
- 52 Week High
- CMMB $10.20
- SEGG N/A
- Technical
- Relative Strength Index (RSI)
- CMMB 19.63
- SEGG N/A
- Support Level
- CMMB $3.32
- SEGG N/A
- Resistance Level
- CMMB $3.86
- SEGG N/A
- Average True Range (ATR)
- CMMB 0.28
- SEGG 0.00
- MACD
- CMMB -0.03
- SEGG 0.00
- Stochastic Oscillator
- CMMB 2.65
- SEGG 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About SEGG Lottery.com Inc. Common Stock
Lottery.com Inc is a provider of domestic and international lottery products and services. As an independent third-party lottery game service, the Company offers a platform that it developed and operates to enable the remote purchase of legally sanctioned lottery games in the U.S. and abroad. The Company's revenue-generating activities are focused on (i) offering the Platform via the Lottery.com app and its websites to users located in the U.S. and international jurisdictions where the sale of lottery games is legal and its services are enabled for the remote purchase of legally sanctioned lottery games; (ii) offering an internally developed, created and operated business-to-business application programming interface of the Platform to enable commercial partners in permitted U.S.